Get the Stockscreener App
1.13
8.13%
-0.10
After Hours:
1.11
-0.02
-1.77%
Mural Oncology Plc stock is traded at $1.13, with a volume of 536.60K.
It is down -8.13% in the last 24 hours and down -67.06% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$1.23
Open:
$1.19
24h Volume:
536.60K
Relative Volume:
2.05
Market Cap:
$19.47M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-4.24%
1M Performance:
-67.06%
6M Performance:
-66.37%
1Y Performance:
-75.43%
1-Day Range:
$1.12
$1.25
1-Week Range:
$1.11
$1.37
52-Week Range:
$1.11
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
1.13 | 19.47M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC - Defense World
HC Wainwright Comments on Mural Oncology Q1 Earnings - Defense World
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects - Seeking Alpha
HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00 - Defense World
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
Mural Oncology stock target cut to $6 at H.C. Wainwright By Investing.com - Investing.com UK
Mural Oncology downgraded to Hold from Buy at JonesResearch - TipRanks
Raymond James downgrades Mural Oncology after ovarian cancer failure - TipRanks
Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform - Defense World
Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading - Defense World
Raymond James cuts Mural Oncology stock rating, slashes target to $6 - Investing.com UK
Morgan Stanley cuts Mural Oncology stock rating to Equal-weight By Investing.com - Investing.com UK
Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks
Mural Oncology halts ovarian cancer drug development By Investing.com - Investing.com South Africa
Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% - Yahoo
Mural Oncology sinks on nemvaleukin miss in ovarian cancer - BioWorld MedTech
Mural Oncology halts ovarian cancer trial By Investing.com - Investing.com South Africa
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Jones Trading cuts Mural Oncology stock rating to hold By Investing.com - Investing.com UK
Mural Oncology halts ovarian cancer trial - Investing.com India
Mural Oncology halts ovarian cancer drug development - Investing.com India
Mural Oncology to Stop Development of Nemvaleukin for Ovarian Cancer; Shares Sink Pre-Bell - MarketScreener
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - The Manila Times
Clinical Trial Setback: Mural's Cancer Drug Falls Short in Phase 3 Ovarian Cancer Study - Stock Titan
Acquisition Of MSC Lung Cancer Screening Test Sends Shares Of This Micro Cap Higher - The Globe and Mail
Mural Oncology (MURA) Expected to Announce Earnings on Tuesday - Defense World
Q1 EPS Estimates for Mural Oncology Reduced by HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Mural Oncology (NASDAQ:MURA) - Defense World
Mural Oncology enters agreement for share sales By Investing.com - Investing.com South Africa
Mural Oncology enters agreement for share sales - Investing.com
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Mural Oncology Slashes Losses by 42% as Two Major Cancer Trial Results Approach - StockTitan
Mural Oncology CEO Caroline Loew sells shares worth $14,491 - Investing.com
Mural oncology officer sells shares worth $9,308 - Investing.com India
Mural oncology officer sells shares worth $9,308 By Investing.com - Investing.com South Africa
Mural Oncology's chief medical officer sells $51,293 in shares - Investing.com India
Mural Oncology’s chief medical officer sells $51,293 in shares - Investing.com
Exclusive: Mural Oncology Unveils Next-Gen Cancer Treatment Strategy at Major Healthcare Conference - StockTitan
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Mural Oncology plc (NASDAQ:MURA) Short Interest Update - MarketBeat
Alkermes plc (ALKS) reports earnings - Quartz
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully - Yahoo Finance
Mural Oncology (NASDAQ:MURA) Trading 8.8% HigherHere's What Happened - MarketBeat
Mural Oncology (NASDAQ:MURA) Trading 8.8% Higher – Here’s Why - Defense World
Jones Trading sets $16 target on Mural Oncology stock By Investing.com - Investing.com Nigeria
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Geode Capital Management LLC Purchases 4,731 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - The Manila Times
Mural Oncology Expands Pipeline with Two Novel Cancer Therapies, Advances Key Clinical Trials - StockTitan
Mural Oncology's chief legal officer sells $8,354 in shares By Investing.com - Investing.com Australia
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):